Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Transdermal buspirone covered under U.S. patent

June 7, 1996

Compounds with high affinity for 5-HT1A and/or D2 receptors reported by E. Merck

June 7, 1996

CCD-3693 clinical trials scheduled

June 7, 1996

Bristol-Myers Squibb describes compounds with melatonergic properties

June 7, 1996

Pfizer reveals migraine treatment

June 7, 1996

Controlled-release oxycodone HCl now on U.S. shelves

June 7, 1996

More tachykinin antagonists described by Merck & Co.

June 7, 1996

Clinical trials on Diatide's Sn-117m DTPA

June 7, 1996

Tachykinin NK1 antagonists described by Ciba-Geigy

June 7, 1996

Production of recombinant human basic fibroblast growth factor covered by U.S. patent

May 31, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 4, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...